Dehydrobenzperidol
Brand names,
Dehydrobenzperidol
Analogs
Dehydrobenzperidol
Brand Names Mixture
Dehydrobenzperidol
Chemical_Formula
C10H16NO+
Dehydrobenzperidol
RX_link
http://www.rxlist.com/cgi/generic3/edrophonium.htm
Dehydrobenzperidol
fda sheet
Dehydrobenzperidol
msds (material safety sheet)
Dehydrobenzperidol
Synthesis Reference
No information avaliable
Dehydrobenzperidol
Molecular Weight
166.24 g/mol
Dehydrobenzperidol
Melting Point
No information avaliable
Dehydrobenzperidol
H2O Solubility
Appreciable as liquid hydrochloride salt
Dehydrobenzperidol
State
Liquid
Dehydrobenzperidol
LogP
-2.95
Dehydrobenzperidol
Dosage Forms
Liquid for injection
Dehydrobenzperidol
Indication
For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.
Dehydrobenzperidol
Pharmacology
Edrophonium is a short and rapid-acting anticholinesterase drug. Its effect is manifest within 30 to 60 seconds after injection and lasts an average of 10 minutes. Edrophonium's pharmacologic action is due primarily to the inhibition or inactivation of acetylcholinesterase at sites of cholinergic transmission. Muscarinic receptors are found throughout the body, especially on muscle. Stimulation of these receptors causes to muscle contraction. In myasthenia gravis the body's immune system destroys many of the muscarinic receptors, so that the muscle becomes less responsive to nervous stimulation. Edrophonium chloride increases the amount of acetylcholine at the nerve endings. Increased levels of acetyl choline allow the remaining receptors to function more efficiently.
Dehydrobenzperidol
Absorption
Rapidly absorbed.
Dehydrobenzperidol
side effects and Toxicity
With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis).
Dehydrobenzperidol
Patient Information
No information avaliable
Dehydrobenzperidol
Organisms Affected
Humans and other mammals